Mission Bio, which provides targeted single-cell DNA analysis and precision genomics, recently launched sales in China following a distribution agreement with the global genomics services provider, Novogene.
Hannah Viernes, senior director of product management at Mission Bio, told us the partnership addresses “high interest and pent up demand for single-cell DNA sequencing globally.”
“This is across key research and translational oncology segments that are moving into single-cell for a more precise way of looking at cellular and genetic heterogeneity,” she added.
According to the company, recent reports suggest the country’s DNA sequencing market will reach $2.7bn by 2022, up from $1.1bn in 2017. The in vitro diagnostics (IVD) market – estimated at $3bn in 2017 – is projected to double by 2022.
“China is one of the largest growing markets in single-cell sequencing,” said Viernes.
Drug development
The Mission Bio Tapestri Platform detects rare cancer subclones and co-occurring cancer mutations to measure therapy response and disease progression, according to the company, which closed a $30m Series B funding round in December 2018.
An investor, LabCorp in March of this year announced a collaboration with Mission Bio, through which it will be the first global contract research organization (CRO) to offer services on the Mission Bio Tapestri Platform.
More than a dozen institutions are using the platform, including researchers from the University of Pennsylvania and the University of California San Francisco, which used the technology to track and monitor cancer evolution to develop new therapies in patients with Acute Myeloid Leukemia (AML).
